{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:08:53Z","timestamp":1777928933144,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Med Screen"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare, in a primary human papillomavirus screening setting, two different validated human papillomavirus tests, considering their analytical and clinical screening performances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In Tuscany, a human papillomavirus screening program was implemented in 2013. Hybrid capture 2 (Qiagen) was used for testing until May 2016, when it was replaced by the cobas\n                      <jats:sup>\u00ae<\/jats:sup>\n                      4800 human papillomavirus test (Cobas; Roche). We evaluated the performance of Hybrid capture 2 and Cobas on: the same screening population in two different periods (before and after changing to Cobas); the same Hybrid capture 2-positive consecutive samples. Discordant samples (Hybrid capture 2-positive\/Cobas negative) were typed on the L1 gene (reverse line blot, AB Analitica) and E6\/E7 genes (BD Onclarity assay).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the considered time period ( n\u2009=\u200937,775), human papillomavirus positivity was 9.8% and 7.4%, respectively, for Hybrid capture 2 and Cobas ( p\u2009&lt;\u20090.0001). At immediate colposcopy, the cervical intraepithelial neoplasia, grade 2 positive predictive value was, respectively, 23.8% and 34% ( p\u2009&lt;\u20090.001). At one-year recall, human papillomavirus persistence was, respectively, 40.6% and 62.2% ( p\u2009&lt;\u20090.0001). Of Hybrid capture 2-positive re-tested samples ( n\u2009=\u2009620), 32.4% were Cobas negative. Of discordant samples typed on L1, 7% were positive for the 12 high-risk human papillomavirus. Of the samples found to be negative for the 12 high-risk human papillomavirus types on L1, 14.5% were positive on E6\/E7 typing. Among the discordant samples, the only two cervical intraepithelial neoplasia (CIN) grade 3 lesions were non-high-risk human papillomavirus positive on both L1 and E6\/E7 typing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>At baseline, Hybrid capture 2 showed greater human papillomavirus positivity and a lower CIN2+ positive predictive value than Cobas, which was more specific than Hybrid capture 2 in detection of high-risk human papillomavirus: 80% of discordant samples were confirmed as high-risk human papillomavirus negative. This higher analytical specificity determined the non-identification of two CIN3 lesions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0969141321992820","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T06:35:49Z","timestamp":1613198149000},"page":"472-479","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Hybrid capture 2 and cobas\u00ae 4800: Comparison of performance of two clinically validated tests for human papillomavirus primary screening of cervical cancer"],"prefix":"10.1177","volume":"28","author":[{"given":"A","family":"Mongia","sequence":"first","affiliation":[{"name":"Regional Cancer Prevention Laboratory \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"},{"name":"General Laboratory \u2013 Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-427X","authenticated-orcid":false,"given":"G","family":"Pompeo","sequence":"additional","affiliation":[{"name":"Regional Cancer Prevention Laboratory \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Sani","sequence":"additional","affiliation":[{"name":"Regional Cancer Prevention Laboratory \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Burroni","sequence":"additional","affiliation":[{"name":"Regional Cancer Prevention Laboratory \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Fantacci","sequence":"additional","affiliation":[{"name":"Regional Cancer Prevention Laboratory \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"},{"name":"Medically Assisted Procreation Unit, Valdichiana Hospital (AUSL Toscana sud est), Cortona (AR), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Bisanzi","sequence":"additional","affiliation":[{"name":"Regional Cancer Prevention Laboratory \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Cellai","sequence":"additional","affiliation":[{"name":"Regional Cancer Prevention Laboratory \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Ventura","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-0163","authenticated-orcid":false,"given":"F","family":"Bottari","sequence":"additional","affiliation":[{"name":"European Institute of Oncology (IEO), Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Carozzi","sequence":"additional","affiliation":[{"name":"Regional Cancer Prevention Laboratory \u2013 Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"bibr1-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"bibr2-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61416-0"},{"key":"bibr3-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70360-2"},{"key":"bibr4-0969141321992820","doi-asserted-by":"publisher","DOI":"10.3310\/hta13510"},{"key":"bibr5-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70296-0"},{"key":"bibr6-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp367"},{"key":"bibr7-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"bibr8-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2015.06.006"},{"key":"bibr9-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(09)00540-X"},{"key":"bibr10-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70096-8"},{"key":"bibr11-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05552-11"},{"key":"bibr12-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058153"},{"key":"bibr13-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01366-15"},{"key":"bibr14-0969141321992820","first-page":"1394","volume":"11","author":"Castle PE","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"bibr15-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(02)00187-7"},{"key":"bibr16-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01047-13"},{"key":"bibr17-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00824-08"},{"key":"bibr18-0969141321992820","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.05.020"}],"container-title":["Journal of Medical Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0969141321992820","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0969141321992820","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0969141321992820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:25:19Z","timestamp":1777677919000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0969141321992820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/0969141321992820"],"URL":"https:\/\/doi.org\/10.1177\/0969141321992820","relation":{},"ISSN":["0969-1413","1475-5793"],"issn-type":[{"value":"0969-1413","type":"print"},{"value":"1475-5793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]}}}